Evaluation of 1-Year Follow-up of Patients Included in the Registry of Clinical Practice in Patients at High Cardiovascular Risk (REACT)
Arq Bras Cardiol. 2021; 116(1):108-116 Doi: 10.36660/abc.20190885
Leia mais
Publicações de Pedro Gabriel Melo de Barros e Silva [7]
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
N Engl J Med 383;22 DOI: 10.1056/NEJMoa2029603
Leia maisA randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial
American Heart Journal, vol. 231 Doi: 10.1016/j.ahj.2020.10.001
Leia maisEvaluation of 1-Year Follow-up of Patients Included in the Registry of Clinical Practice in Patients at High Cardiovascular Risk (REACT)
Arq Bras Cardiol. 2020 Dec 16:S0066-782X2020005014203. Doi:10.36660/abc.20190885
Leia maisOne year follow-up Assessment of Patients Included in the Brazilian Registry of Acute Coronary Syndromes (ACCEPT)
Arq Bras Cardiol. 2020; 114(6):995-1003 Doi: 10.36660/abc.20190879
Leia maisEFFECT OF LOADING DOSE OF ATORVASTATIN PRIOR TO PLANNED PERCUTANEOUS CORONARY INTERVENTION ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ACUTE CORONARY SYNDROME: THE SECUREPCI RANDOMIZED CLINICAL TRIAL.
JAMA. 2018 Apr 3;319(13):13311340 DOI: 10.1001/jama.2018.2444
Leia mais